Have a feature idea you'd love to see implemented?
Let us know!
BOLT Bolt Biotherapeutics Inc
Price (delayed)
$0.6504
Market cap
$24.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.74
Enterprise value
$35.81M
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach
Highlights
The revenue has soared by 65% YoY
Bolt Biotherapeutics's gross profit has soared by 65% YoY
The EPS has grown by 15% YoY but it has contracted by 4.8% from the previous quarter
The company's net income rose by 14% YoY but it fell by 5% QoQ
The quick ratio has contracted by 42% YoY and by 24% from the previous quarter
The equity is down by 40% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of BOLT
Market
Valuations
Earnings
Shares outstanding
38.26M
Market cap
$24.89M
Enterprise value
$35.81M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
2.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.21
Revenue
$11.17M
EBIT
-$66.17M
EBITDA
-$61.26M
Free cash flow
-$64.08M
Per share
Balance sheet
Liquidity
EPS
-$1.74
Free cash flow per share
-$1.68
Book value per share
$2.25
Revenue per share
$0.29
TBVPS
$3.26
Total assets
$124.18M
Total liabilities
$38.32M
Debt
$18.89M
Equity
$85.86M
Working capital
$58.73M
Debt to equity
0.22
Current ratio
4.28
Quick ratio
4.22
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
-548.6%
Gross margin
100%
Net margin
-592.6%
Operating margin
-695.3%
Return on assets
-43.9%
Return on equity
-61.4%
Return on invested capital
-46.4%
Return on capital employed
-62.3%
Return on sales
-592.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BOLT stock price
How has the Bolt Biotherapeutics stock price performed over time
Intraday
0.08%
1 week
1.94%
1 month
8.84%
1 year
-31.54%
YTD
-41.93%
QTD
0.37%
Financial performance
How have Bolt Biotherapeutics's revenue and profit performed over time
Revenue
$11.17M
Gross profit
$11.17M
Operating income
-$77.64M
Net income
-$66.17M
Gross margin
100%
Net margin
-592.6%
The revenue has soared by 65% YoY
Bolt Biotherapeutics's gross profit has soared by 65% YoY
The net margin has grown by 48% YoY but it has contracted by 6% from the previous quarter
Bolt Biotherapeutics's operating margin has increased by 42% YoY but it has decreased by 5% from the previous quarter
Growth
What is Bolt Biotherapeutics's growth rate over time
Valuation
What is Bolt Biotherapeutics stock price valuation
P/E
N/A
P/B
0.29
P/S
2.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.21
The EPS has grown by 15% YoY but it has contracted by 4.8% from the previous quarter
The equity is down by 40% YoY and by 18% from the previous quarter
BOLT's P/B is 28% below its last 4 quarters average of 0.4
The revenue has soared by 65% YoY
The stock's P/S is 51% less than its last 4 quarters average of 4.5
Efficiency
How efficient is Bolt Biotherapeutics business performance
The ROS has grown by 48% YoY but it has contracted by 6% from the previous quarter
The ROE fell by 32% YoY and by 19% QoQ
Bolt Biotherapeutics's ROIC has decreased by 24% YoY and by 17% from the previous quarter
Bolt Biotherapeutics's ROA has decreased by 24% YoY and by 16% from the previous quarter
Dividends
What is BOLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BOLT.
Financial health
How did Bolt Biotherapeutics financials performed over time
The quick ratio has contracted by 42% YoY and by 24% from the previous quarter
The company's current ratio fell by 42% YoY and by 25% QoQ
The debt is 78% less than the equity
BOLT's debt to equity is up by 47% YoY and by 16% from the previous quarter
The equity is down by 40% YoY and by 18% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.